Potential Reduction of Cystic Fibrosis Pulmonary Flare-Ups

Trial Objective

The purpose of this research study is to determine if an investigational medication can reduce inflammation, tissue scarring, and the number of pulmonary exacerbations, or episodes when breathing is more difficult, in people with cystic fibrosis (CF).

Potential Reduction of Cystic Fibrosis Pulmonary Flare-Ups

Our researchers are studying if two different doses of this medication can be taken safely without causing too many side effects. Current treatments for pulmonary exacerbations (inhaled, oral or intravenous antibiotics and hospitalization) and therapies for inflammation (corticosteroids, antibiotics and high-dose ibuprofen) can cause short- and long-term toxic effects in the body, and may or may not be effective. This medication may stop chronic inflammation and the scarring it can produce without suppressing the immune system.


This trial is active and currently recruiting.

How to Participate

For more information, contact Chris Verano at 303.398.1808 or complete the form below.

Who Can Participate

People with cystic fibrosis who are 12 or older may be eligible to participate.

Estimated Time Commitment

9 visits (15 hours over about 32 weeks)

This study involves 28 weeks of active dosing with the study drug plus a safety follow-up visit at Week 32.

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Corbus Pharmaceuticals, Inc.




Any Gender

Principal Investigators

Request More Information